Osteosarcoma is the most common primary malignancy of bone and characterized by an appendicular primary tumor with a high rate of metastasis to the lungs. Unfortunately, there is no effective strategy to treat osteosarcoma in current clinical practice. In this study, the anticancer effects and potential mechanisms of nifuroxazide, an oral nitrofuran antibiotic, on two osteosarcoma cell lines were investigated. The results of the antiproliferative activity in vitro showed that nifuroxazide inhibited cell proliferation of UMR106 and MG63 cells in a dose- and time-dependent manner. Interestingly, nifuroxazide showed low toxicity to non-tumor cells (HEK 293 T). In addition, ROS-mitochondrial mediated apoptosis was observed after treatment of nifuroxazide. Moreover, nifuroxazide could significantly inhibit osteosarcoma cells migration and invasion via p-Stat3, MMP-2 and MMP-9 mediated signaling pathway. Taken together, our results suggested that nifuroxazide could be a promising agent for osteosarcoma treatment by inhibiting cell proliferation, inducing cell apoptosis and impairing cell migration and invasion.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Whelan JS, Davis LE (2018) Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol 36:188–193
Wang W, Zhao HF, Yao TF, Gong H (2018) Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Investig New Drugs. https://doi.org/10.1007/s10637-018-0684-8
Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML (2009) Juvenile myelomonocytic leukemia: a report from the 2nd international JMML symposium. Leuk Res 33:355–362
Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F et al (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125:2586–2594
Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM et al (2018) Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med 24:178–185
Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8:705–718
Tomita K, Kawahara N, Murakami H, Demura S (2006) Total en bloc spondylectomy for spinal tumors: improvement of the technique and its associated basic background. J Orthop Sci 11:3–12
Deng ZP, Ding Y, Puri A, Wang EH, Gulia A, Durban C et al (2015) The surgical treatment and outcome of nonmetastatic extremity osteosarcoma with pathological fractures. Chin Med J 128:2605–2608
Biazzo A, De Paolis M (2016) Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 82:690–698
Akagunduz OO, Kamer SA, Kececi B, Demirag B, Oniz H, Kantar M et al (2016) The role of radiotherapy in local control of nonextremity Ewing sarcomas. Tumori 102:162–167
Wang CC, Jing JH, Cheng L (2018) Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Investig New Drugs 36:1116–1132
Ritter J, Bielack SS (2010) Osteosarcoma. Ann Oncol 21(Suppl 7):vii320–vii325
Xue HQ, Li J, Xie HZ, Wang YD (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14:1232–1244
Würth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F (2016) Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today 21:190–199
Shim JS, Liu JO (2014) Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 10:654–663
Zhu Y, Ye T, Yu X, Lei Q, Yang F, Xia Y et al (2016) Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep 6:20253
Ye TH, Yang FF, Zhu YX, Li YL, Lei Q, Song XJ et al (2017) Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis 8:e2534
Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X et al (2015) Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis 6:e1701
Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F et al (2012) Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 135:445–458
Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L et al (2014) The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS One 9:e85887
Thandapani P, Aifantis I (2017) Apoptosis, up the ante. Cancer Cell 32:402–403
Hahn WC (2004) Cancer: surviving on the edge. Cancer Cell 6:215–222
Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, −6, and −7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326
Benhar M, Forrester MT, Hess DT, Stamler JS (2008) Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320:1050–1054
Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43:95–118
Singh PK, Roukounakis A, Frank DO, Kirschnek S, Das KK, Neumann S et al (2017) Dynein light chain 1 induces assembly of large Bim complexes on mitochondria that stabilize Mcl-1 and regulate apoptosis. Genes Dev 31:1754–1769
Pyakurel A, Savoia C, Hess D, Scorrano L (2015) Extracellular regulated kinase phosphorylates mitofusin 1 to control mitochondrial morphology and apoptosis. Mol Cell 58:244–254
Bhola PD, Letai A (2016) Mitochondria-judges and executioners of cell death sentences. Mol Cell 61:695–704
Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J et al (2015) A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov 5:920–931
Ellegast J, Barth TF, Schulte M, Bielack SS, Schmid M, Mayer-Steinacker R (2011) Metastasis of osteosarcoma after 16 years. J Clin Oncol 29:e62–e66
Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z et al (2015) IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-kappaB signaling. J Clin Invest 125:1839–1856
Hattori H, Yamamoto K (2012) Lymph node metastasis of osteosarcoma. J Clin Oncol 30:e345–e349
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67–68
Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM (2007) Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52:1388–1396
This work was supported by the Support Program for Science and Technology of Sichuan Province (2017SZ0106).
Conflict of interest
The authors confirm that they have no conflict of interest with the content of this article.
This article does not contain studies with human participants or animals performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Luo, Y., Zeng, A., Fang, A. et al. Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma. Invest New Drugs 37, 1006–1013 (2019). https://doi.org/10.1007/s10637-019-00724-4